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Abstract: A novel and efficient synthetic route was developed for the prepar-
ation of protoberberine derivatives. A methodology, designed primarily to con-
trol the substitution patterns on the terminal rings, was used to access a small 
array of these compounds. An initial biological profiling suggested an antican-
cer potential of the synthesised derivatives, while structure-based target fishing 
identified their potential targets and established a rational basis for further 
structural modifications. Although the activities need further improvement, the 
study demonstrated that the described approach may be useful in the discovery 
of novel lead compounds. 
Keywords: cytotoxic properties; protoberberine; privileged structure; synthesis; 
target fishing. 
INTRODUCTION 
Natural products represent a valuable source of biologically active com-
pounds and have played an important role in the drug discovery process.1–9 In 
recent years, their influence on the research in pharmaceutical companies has 
arguably been on the decline mainly due to the advent of combinatorial chemistry 
and the expectations that it may secure access to a large number of new lead 
compounds.8 Even so, in the period between 2000 and 2006, a total of 26 new 
natural products or natural products-derived drugs were launched worldwide with 
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many more being in clinical trials, suggesting that naturally occurring com-
pounds continue to play a prominent role in drug discovery.10 Undoubtedly use-
ful as a starting point in the finding of new therapeutics, they also impose some 
limitations as a result of often insufficient availability and complex structural 
requirements. Therefore, the development of similar analogues with comparative 
biological properties is highly desirable and may provide access to a chemical 
space not approachable by convenient combinatorial synthesis.11,12 In recent 
years, various tools have been developed in order to facilitate the process of 
creating collections of natural products-derived compounds.13 Our interest in nat-
ural products inspired the search for new anticancer derivatives, which led to the 
study of polycyclic protoberberines.14–16 This class of compounds shows a wide 
range of biological activities including anticancer properties, which are associ-
ated with several mechanistic pathways. It was proposed that they bind to the 
DNA B-form by partial intercalation, showing AT base pair specificity.17 In 
addition, they may interact with polyriboadenylic acid, an important factor for 
the stability and maturation of mRNA.18 Some studies also suggested that proto-
berberines inhibit topoisomerase through stabilisation of the enzyme–DNA com-
plex.19,20 The most frequent protoberberinic structures (Fig. 1, represented by 
pseudopalmatine, xylopinine and gusanlung D) are typically characterised by a 
tetracyclic core in which rings A and D are aromatic while ring C diverges in its 
oxidation state.  
Fig. 1. Protoberberines and related nat-
ural products. 
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The substitution patterns usually present in these compounds are the result of 
the oxygenation of rings A and D. Related to protoberberins are dihydrogam-
birtannine and ketoyobyrine while some similarities exist with the structures of 
emetinoides and benzylisoquinolines as well (Fig. 1).21–24 The present study to 
find new classes of compounds with anticancer potential was initiated with hopes 
to enter a new chemical space defined by these natural products and the initial 
results will be discussed further in this text. 
RESULTS AND DISCUSSION 
Chemistry 
Analysis of the structural properties of compounds outlined in Fig. 1 and rel-
ated derivatives led to two associated scaffolds, 1 and 2 (Fig. 2). Their calculated 
volumes are 155 and 192 Å3, respectively, which, compared with the average 
calculated volumes of protein cavities, generally leave enough space for their 
wider functionalisation.25 
Fig. 2. Protoberberine-based scaffolds. 
Although all compounds could be considered as derivatives of these two, the 
oxidation level and substitution patterns of the terminal rings vary. In order to 
increase synthetic efficiency and potentially to expand the chemical space later 
via diversity orientated synthesis, it was essential to develop a flexible route that 
will diverge to various derivatives via a common intermediate. These criteria 
were fulfilled by the synthetic route outlined in Scheme 1.26 Quaternisation of 
pyridine with allyl bromide (3a) afforded the pyridinium salt 4 in a good yield. 
Further reaction of 4 with Grignard reagent furnished, as expected, two regioiso-
meric products 5 and 6, which were subsequently reduced using NaBH3CN to 
eliminate the labile enamine functionality.27–29 At this stage the regioisomeric 
products were separated and compound 7 was submitted to typical conditions for 
the Heck reaction.30,31 The expected diene 9 was obtained in 26 % yield and set 
the stage for key transformations expected to lead to the target compounds. 
Diels–Alder reaction of diene 9 with dimethyl acetylenedicarboxylate (DMAD) 
afforded the tricyclic cycloadduct 10.32–34 After some experimentation, it was 
found that careful oxidation of 10 produced both the tetrahydro- and oxo-type 
skeleton, 11 and 12, respectively, found in the above-mentioned natural pro-
ducts.35–37 Thus, by developing this route, three classes of natural compound-rel-
ated derivatives based on scaffold 1/2, type 10–12, could be prepared. 
Next, this synthetic route was applied to the preparation of tetrahydro- and 
oxoprotoberberine derived compounds (Scheme 2). The synthesis of diene 17 
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was initiated by the alkylation of isoquinoline 13 followed by the same reaction 
sequence as outlined in Scheme 1. Diene 17 proved to be sufficiently reactive in 
boiling toluene to afford the cycloadducts 18 with either a mono- or bis-activated 
alkyne. Exploration of the oxidative processes secured access to both tetrahydro- 
and oxoprotoberberine derivatives. Careful control of the reaction conditions, pri-
marily a lower amount of MnO2, produced tetrahydroprotoberberines 19, while 
larger quantities of the oxidant afforded the oxo derivatives 20. Monitoring the 
reaction by thin layer chromatography (TLC) was important because the oxo 
compound 20 was formed via further oxidation of the initially formed tetrahydro 
derivative 19. This was facilitated by the different, characteristic TLC appearance 
of these compounds (orange–red for 19 vs. grey–blue for 20).  
 
Scheme 1. Synthesis of pyridine derivatives. 
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Scheme 2. Synthesis of protoberberine derivatives. 
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Finally, dihydro-β-carboline 21 was annulated using the same reaction 
sequence to produce compound 26, possessing a dihydrogambirtanin core, and 
oxo derivative 27, with a ketoyobirine structure, via the common intermediate 25 
(Scheme 3). 
 
Scheme 3. Synthesis of dihydrogambirtanin and ketoyobirine derivatives. 
The developed synthetic route provided in a straightforward manner access 
to several classes of protoberberine-like compounds derived from pyridine, iso-
quinoline and 3,4-dihydro-β-carboline. Importantly, it has the potential to diver-
sify further the target structures via functionalization of the common diene inter-
mediate.  
Biology 
The in vitro cytotoxicity of selected synthesised compounds was studied 
against three human cancer cell lines, human cervix adenocarcinoma (HeLa), 
human melanoma (Fem-x) and human chronic myelogenous leukaemia (K562). 
For this purpose, a tetrazolium-based colorimetric assay (MTT) was employed, 
while the activity of the tested compounds was compared with that of cisplatin as 
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a positive control (Table I). The results of the in vitro cytotoxic activity are 
expressed as IC50 in μM. 
TABLE I. Cytotoxicity of the synthesised protoberberine derivatives 
Entry Compound FemXa HeLaa K562a 
a 25 81.8±9.3 68.5±5.3 28.8±9.7 
b 18a 88.5±9.0 82.9±12.4 53.3±2.4 
c 20ab 178.2±2.0 134.5±7.0 101.2±11.2 
d 20ac >200 >200 >193 
e 20bb 187.7±8.9 120.8±11.8 85.9±21.0 
f 20bc >179 >179 >165 
g 18b 65.5±0.5 38.1±8.9 24.7±0.2 
h 18c 157.9±2.4 152.1±7.6 87.1±14.9 
i 20c 188.1±13.4 92.8±6.3 85.9±1.1 
j 19a 86.7±8.5 93.8±3.6 52.4±7.4 
k 11 178.2±12.6 >200 104.4±7.6 
l 26 136.7±8.3 48.8±3.6 36.1±10.1 
m 19c 150.7±14.5 133.3±10.2 46.7±5.9 
n 19b 172.6±10.0 188.4±0.5 67.7±12.3 
o cisplatin 11.1±6.9 6.4±0.2 6.3±0.7 
aThe results are presented as mean IC50 ± standard deviation, µM; bcompounds crystallised upon prepar-
ation of the sample; ccompounds crystallised upon preparation of the sample and the shown results were 
obtained with a solution, after filtration and separation of the crystals 
Amongst the studied cell lines, K562 was shown to be the most sensitive 
towards the tested compounds with derivatives 18b and 25 being the most active 
(Table I, K562: entries g and a). The HeLa cell line was less responsive and two 
compounds, 18b and 26 (Table I, HeLa: entries g and l), exhibited better bio-
logical profiles than the others. Tested heterocycles demonstrated lowest activity 
against the FemX cell line while compound 18b (Table I, FemX: entry g) was 
again the most active one. The narrow number of compounds prepared for this 
initial investigation cannot allow detailed structure–activity relationship studies 
but some trends could be identified, in particular for the most sensitive K562 cell 
line. In general, derivatives possessing an amide functionality in the oxoprotober-
berine skeleton, (Table I, 20a–c) were less active than the corresponding tertiary 
amines (Table I, e.g., 18b, 19a, 19c, 25, 26) and this trend was general for all 
three cell lines.  
This might suggest that basic properties contribute to a better biological pro-
file, either via influencing the physicochemical features of the compounds or due 
to specific interactions with the target molecules. Regarding the oxidation state of 
the terminal ring, which was either in the cyclohexadiene or the benzene form, no 
significant differences between these derivatives were observed for some com-
pounds (Table I, 25 vs. 26 and 18a vs.19a) but not all (Table I, 18b vs. 19b). 
Finally, the observed activity of the tested compounds suggested that the least 
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active are derivatives prepared via annulation of the pyridine ring, while isoqui-
noline and β-carboline derivatives showed comparable properties. In order to 
gain insight into the mechanism of action of the active compounds, further their 
effects on the cell cycle were explored. The experiments were realised with com-
pounds 19a, 25 and 26 on the HeLa cells. The cells were treated for 24 h with the 
studied derivatives and were then stained with propidium iodide (PI) followed by 
flow cytometry analysis. Representative cell-cycle distributions of HeLa cells 
incubated in the absence or presence of 19a, 25 and 26 for 24 h are shown in Fig. 
3. The obtained DNA histogram indicated that treatment with IC50 or 2×IC50 for 
24 h led to a significant increase in the number of sub-G1 phase cells and a dec-
rease in the number of G1 and G2/M cells after treatment with all three com-
pounds. A further study involved the acridine orange (AO)/ethidium bromide 
(EB) double staining assay to determine the mode of HeLa cells death induced by 
19a, 25 and 26.  
Microphotographs of the treated cells showed that the tested compounds 
induced chromatin condensation (indicated by the arrows in Fig. 4b–d) and nuc-
lear fragmentations (indicated by arrowhead in Fig. 4b–d) processes considered 
to be hallmarks of apoptosis.38 Based on these results, it would be appropriate to 
propose that the promotion of apoptosis is the likely mode of action of syn-
thesised protoberberine compounds. 
Computational chemistry 
The initial biological studies of the compounds outlined in Table I suggest 
that they possess antiproliferative potential, but it is obvious that further struc-
tural modifications are necessary in order to optimize their properties. In order to 
be able to make rational structural variations, a computational study of these 
heterocycles was embarked on with the aim of defining their potential target bio-
molecules. Structure-based target fishing can provide a rational basis for gener-
ating hypotheses regarding the mechanism of action of compounds with estab-
lished biological activity.39,40 Within the framework of this method, high- 
-throughput molecular docking of the investigated compounds was performed 
against a set of biomolecules that are known to bind either a cognate ligand or 
synthetic small molecules. The resulting docking scores were then used to prior-
itize a smaller number of putative targets under the assumption that those targets 
yielding higher docking scores are more likely to be genuine targets in biological 
settings. Despite inherent limitations of the available docking methodologies, this 
approach was demonstrated as useful in identifying a smaller number of putative 
targets for further evaluation.41–46 Since the present aim was to rationalize the 
observed antiproliferative activities, targets were first prioritized based on the 
agreement between docking scores and the determined in vitro activity. This 
allowed the utilisation of all the available experimental data, but necessarily 
assumed that the in vitro cytotoxicity reflects on-target efficacy and was not dispro- 
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Fig. 3. Cell cycle distribution after 24 h continuous action of compounds 19a, 25 and 26 on 
HeLa cells. 
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Fig. 4. Induction of apoptosis in HeLa cells by compounds 25, 19a and 26. 
portionately limited by other factors, such as permeability or active efflux. In 
interpreting the results, this assumption was taken into account, especially con-
sidering the lower solubilities of 20a and 20b. In the second stage of target rank-
ordering, it was assumed that the structural similarity and similarities of the obs-
erved cell-cycle effects of the studied protoberberines suggested that they shared 
a common mode of action. Accordingly, targets with higher overall docking 
scores across all the active protoberberines were considered more likely targets 
than those with a lower sum of docking scores. Data mining of the obtained mat-
rix of the docking results revealed a number of putative targets, which showed 
good correlation to the determined IC50 values. The ten targets that displayed the 
best correlations are listed in Table II. For these ten targets, as an additional rank-
ordering parameter, sums of docking scores across all the active protoberberines 
were calculated and are also given in Table II. It should be noted that these sums 
were derived from normalized docking scores, which comprehensively take into 
account: i) the non-specific contribution of molecular size to docking results,46,47 
ii) the differences between the screened protein structures and iii) the docking 
scores of known ligands relative to those of the investigated compounds. 
The mean Vina docking scores for the 12 protoberberines at all 10 targets are 
summarized in Table III. 
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TABLE II. Summary of the virtual screening results 
Targeta 
(PDB entry) 
K562 HeLa FemX 
Rb Σ δLEc R Σ δLE R Σ δLE 
Bcl-xl (3spf) 0.56 14.78 0.71 11.85 0.85 7.32 
Tubulin (4eb6) 0.61 14.52 0.51 11.85 0.18 7.33 
FTase (1ld8) 0.65 12.97 0.62 10.56 0.61 6.49 
NQO1 (2f1o) 0.62 12.92 0.76 10.43 0.43 6.43 
Akt1 (3qkl) 0.80 10.93 0.64 8.89 0.20 5.53 
c-Met (2wgj) 0.66 10.22 0.78 8.16 0.45 5.08 
Bcl-2 (4aq3) 0.44 9.76 0.46 7.83 0.84 4.85 
CDK2 (2w1h) 0.55 9.61 0.49 7.80 0.38 4.79 
FAK1 (3bz3) 0.69 8.82 0.82 7.12 0.53 4.40 
HSP90 (2wi6) 0.51 8.64 0.68 6.96 0.57 4.25 
aTarget abbreviations used: Bcl-xl – Bcl-2-like protein 1; FTase – protein farnesyltransferase; NQO1 – 
NAD(P)H: quinone dehydrogenase 1; Akt1 – RAC-alpha serine/threonine-protein kinase; c-Met – hepato-
cyte growth factor receptor; Bcl-2 – apoptosis regulator Bcl-2; CDK2 – cyclin-dependent kinase 2; FAK1 
– focal adhesion kinase 1; HSP90 – heat shock protein HSP 90-alpha; bR – correlation factor between 
docking scores and IC50; cΣδLE – sums of docking scores across all the active protoberberines 
TABLE III. Vina docking scores for the studied protoberberines across the 10 highest ranked 
target proteins 



















18b –8.4 –7.6 –9.2 –7.5 –8.9 –9.9 –7.7 –9.8 –8.7 –8.2 
19b –8.4 –7.6 –9.3 –7.7 –8.9 –10.0 –7.7 –9.9 –8.8 –8.3 
18a –7.8 –8.1 –9.0 –6.7 –8.4 –8.8 –7.3 –9.1 –8.3 –7.5 
19a –7.8 –7.8 –9.0 –6.7 –8.7 –8.9 –7.6 –10.0 –8.6 –7.6 
18c –7.1 –7.5 –8.4 –6.5 –8.2 –8.8 –6.2 –8.9 –7.6 –7.6 
19c –7.4 –7.5 –8.9 –6.5 –8.7 –8.6 –7.0 –9.2 –8.2 –7.1 
20b –7.9 –8.0 –8.9 –7.2 –8.6 –9.0 –7.5 –10.5 –8.5 –7.9 
20a –7.8 –7.8 –9.2 –6.7 –8.3 –8.6 –7.3 –9.4 –8.3 –7.5 
20c –7.2 –7.3 –8.7 –6.6 –8.0 –8.4 –6.5 –9.0 –8.3 –7.3 
25 –8.1 –8.8 –9.8 –7.5 –9.3 –9.8 –7.2 –10.4 –8.8 –7.9 
26 –7.9 –8.8 –9.3 –7.6 –9.5 –9.9 –7.1 –10.5 –9.0 –7.9 
11 –7.3 –7.0 –7.6 –5.9 –7.4 –8.7 –6.7 –8.5 –7.7 –6.8 
The obtained results were analyzed with respect to the existing literature 
evidence on the mechanism of action of related compounds. Naturally occurring 
protoberberines are known to interact with a variety of molecular targets result-
ing in antiproliferative and pro-apoptotic effects. Berberine, the best studied rep-
resentative of this compound class, exerts these effects in various tumour cell 
lines through increased formation of reactive oxygen species (ROS), downregul-
ation of anti-apoptotic proteins such as Bcl-2 and Bcl-xl, induction of apoptosis 
through mitochondrial-caspase activation, interaction with DNA and RNAs 
and/or topoisomerase poisoning.48,49 A closely related benzylisoquinoline alka-
loid, sanguinarine, is further known to inhibit microtubule assembly and to 
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modulate the levels of a Bcl-2 protein family member.50,51 Effects similar to 
those of berberine on mitochondrial membrane potential, caspase activation and 
Bcl-2 protein family members have also been described for berbamine and ano-
naine.52–55 When considered in context of the biological profile of well charac-
terized benzylisoquinoline alkaloids, the results of the present virtual target 
screening suggest a similar putative mechanism of action of the newly synthe-
sised derivatives, but also provide a novel potential molecular basis for these 
effects. The cytotoxicity of the studied compounds in myelogenous leukaemia 
K562 cells was found to correlate best with the presumed binding affinities of 
these compounds to Akt1. This finding is consistent with experimental evidence 
suggesting that berberine inhibits Akt1 activity and favours its degradation and 
that this results in reduced tumour cell viability and induction of apoptosis.56,57 
The good correlation between the docking scores at NQO1 and FTase could be 
rationalized in terms of increased ROS formation that could result from the inhi-
bition of these enzymes.58–60 Increased ROS formation is a known effect of pro-
toberberines that could contribute to cell death via multiple pathways. Further-
more, disruption of microtubule assembly could also contribute to cell-cycle 
arrest and induction of apoptosis, although this does not seem to be a major 
determinant of cytotoxicity in the FemX cell line. Conversely, interaction with 
Bcl-2 family proteins showed significant association with in vitro activity in 
FemX as well as the other two cell lines. As presented in Table III, most of the 
compounds that were found to be inactive in the HeLa and FemX cell lines have 
lower docking scores than the active protoberberines, although these differences 
are not large. These findings might be attributed to differential susceptibility of 
the tested cell lines to inhibition of the proposed putative targets, but also points 
to the fact that the developed compounds exhibit low specificity binding and lack 
significant potency at individual targets. To investigate the possibility of further 
structural optimization using the developed synthetic strategy, the molecular 
aspect of the interaction between the studied compounds and their likely targets 
was analysed. In terms of structural determinants of the observed activity, the 
interaction of the studied protoberberines with most of the identified putative 
targets is largely non-specific and governed by hydrophobic interactions. This is 
best exemplified by the proposed binding modes of the studied structures at the 
Bcl-xl protein. As shown in Fig. 5a, they occupy a hydrophobic pocket which is 
also exploited by a potent small molecule inhibitor BM501.61 Lacking any 
strictly directional interactions with the binding site residues, compounds 18b, 
20c and 25, shown in Fig. 5a as representative structures, differ in their binding 
modes largely due to differences in size and polarity. The smallest, least polar 
and most potent of them, 18b, is able to localize deep in the binding pocket, 
whereas the increased size and polarity of the other two compounds allow them 
to fit only partially into the deep pocket, with reduced binding affinity as a con-
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sequence. Some of the other potential targets, on the other hand, seem to show a 
greater tolerance for variations in size and interact more favourably with the ext-
ended structures. In the instance of binding to the vinblastine related site at the 
heterodimeric interface of tubulin (Fig. 5b), 25 shows the highest target affinity 
due to a greater number of hydrophobic contacts as opposed to 18a and 18b.  
 
Fig. 5. Binding modes at: a) Bcl-xl (PDB: 3spf), 18b (blue), 25 (orange), 20c (yellow); 
b) tubulin (PDB: 4eb6), 18b (blue), 18a (red), 25 (orange); c) FTase (PDB1ld8), 
18b (blue), 18a (green). 
As exemplified by the differences in docking scores between the latter two 
closely related structures (Table III, –8.1 and –7.6, respectively), variation of 
substituents in ring D, easily accessible by the developed synthetic route, could 
present the basis for improving the affinity and specificity in targeting tubulin. 
While C11 carboxyl substituents might cause steric hindrance, variation of C10 
substituents is likely to allow the exploration of the deep adjacent pocket and inc-
rease specificity through H-bonding. The potential usefulness of varying these 
substituents is also exemplified by the putative binding modes of 18a and 18b in 
the FTase active site, as illustrated in Fig. 5c. The presence and nature of these 
substituents seem to play noteworthy roles in the orientation of the relatively 
rigid polycyclic core in the binding sites, which consequently affects the extent 
of hydrophobic contacts made with the protein. The overall observations suggest 
that careful variation of these substituents could impart target selectivity to an 
otherwise promiscuous compound class and that it could potentially present the 
basis for advancing the multi-targeted mechanism of action of naturally occurring 
or synthesised protoberberines to a more specific one. Further biochemical profil-
ing of activity on these targets is therefore highly warranted. 
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EXPERIMENTAL 
Chemistry  
General. The NMR spectra were recorded on a Bruker Avance III (500 MHz) or Varian 
Gemini 2000 (200 MHz) spectrometers. Chemical shifts (δ) are given in ppm downfield from 
tetramethylsilane as the internal standard. Deuterochloroform was used as the solvent, unless 
otherwise stated. Mass spectral data were recorded using an Agilent MSD TOF spectrometer 
coupled with Agilent 1200 HPLC or an Agilent Technologies 5975C MS coupled with an 
Agilent Technologies 6890N GC. The IR spectra were recorded on an IR Thermo Scientific 
Nicolet iS10 (4950) spectrometer. Melting points were determined using a Gallenkamp 
melting point apparatus and are uncorrected. Flash chromatography employed silica gel 60 
(230–400 mesh) while thin layer chromatography was performed using alumina plates with a 
0.25 mm silica layer (Kieselgel 60 F254, Merck). The compounds were visualised by staining 
with potassium permanganate solution or Dragendorff reagent. All solvents were distilled 
before the use. Petroleum ether refers to fraction boiling in the 40–60 °C range. 
Spectral data for the synthesised compounds and selected NMR spectra are given in 
Supplementary material to this paper. 
Synthetic procedures 
3,4-Dihydro-β-carboline, 6,7-dimethoxyisoquinoline and 3-bromo-2-iodoprop-1-ene 
were synthesised following literature procedures.62-64  
General procedure for the preparation of iminium salts. Heterocyclic compound (2.5 
mmol; isoquinoline, 3,4-dihydro-β-carboline, pyridine) and 3-bromo-2-halogenprop-1-ene 
(1.1 eq) were heated in acetonitrile (10 mL) at 80 °C for 4 h. The mixture was then cooled to 
room temperature, the acetonitrile was removed under reduced pressure and the crude salt was 
washed with dry diethyl ether (3×5 mL). The product was dried under reduced pressure at 
room temperature. The synthesised salts were used in the next step without further charac-
terisation.  
General procedure for the addition of allylmagnesium bromide to the iminium salts. 
Magnesium turnings (1.06 g, 44 mmol) were added to a two-necked round-bottom flask 
assembled with a reflux condenser, which had been flame dried and allowed to cool under a 
stream of nitrogen. Dry diethyl ether (5 mL) was added to flask under stirring. Then, the 
round-bottom flask was cooled to 0 °C in an ice bath. A solution of allyl bromide (4.84 g, 40 
mmol, 3.4 mL) in dry diethyl ether (40 mL) was slowly added to the flask and the reaction 
mixture was stirred for 1 h at room temperature. The iminium salt (16 mmol) was then added 
to solution of Grignard reagent and reaction mixture was stirred for 1 h at room temperature. 
Excess of allylmagnesium bromide was destroyed with a saturated solution of ammonium 
sulphate at 0 °C. The organic layer was separated and aqueous layer was extracted with 
diethyl ether (2×25 mL). The combined organic layers were dried over anhydrous sodium 
sulphate. After filtration and removal of the solvent under reduced pressure, the crude ena-
mine was reduced without prior purification. 
General procedure for the reduction of enamines. A crude enamine (1.2 mmol) was dis-
solved in dry MeOH (5 mL) and cooled under stirring to 0 °C. Sodium cyanoborohydride (3.6 
mmol) was then added, and the suspension was acidified with concentrated HCl to pH close to 
3. The resulting mixture was allowed to warm to room temperature and stirring was continued 
for 4 h. 1M NaOH was then added until pH close to 10, the mixture was extracted with 
dichloromethane (3×30 mL), the combined organic layers were washed with water (2×5 mL) 
_________________________________________________________________________________________________________________________
(CC) 2016 SCS. All rights reserved.
Available on line at www.shd.org.rs/JSCS/
 STUDY OF NOVEL SYNTHETIC PROTOBERBERINES 117 
and dried over anhydrous sodium sulphate. After filtration and removal of the solvent, the 
residue was evaporated under reduced pressure and purified by flash chromatography (SiO2). 
General procedure for the synthesis of dienes. A mixture of halogenalkene (0.7 mmol), 
Pd(OAc)2 (10 mol %), PPh3 (20 mol %) and K2CO3 (1.5 eq.) in acetonitrile (10 mL) was 
refluxed under a nitrogen atmosphere for 12 h. After evaporation in vacuo, the residue was 
dissolved in dichloromethane, washed with water and dried over anhydrous sodium sulphate. 
The solid was separated by filtration and the solvent removed under reduced pressure. The 
residue was purified by flash chromatography (SiO2) to afford the product. 
General procedure for the synthesis of cycloadducts. A mixture of diene (0.2 mmol) and 
dienophile (0.24 mmol) in dry toluene (5 mL) was refluxed under a nitrogen atmosphere for 
12 h. The solvent was then evaporated under reduced pressure and the residue was purified by 
flash chromatography (SiO2) to afford the product. 
General procedure for the synthesis of tetrahydroprotoberberines. A mixture of cyclo-
adduct (0.1 mmol) and MnO2 (2.2 mmol) in dry dichloromethane (20 mL) was stirred and 
refluxed under a nitrogen atmosphere. The reaction was monitored by TLC and when com-
pleted (≈30 min), the mixture was cooled to room temperature, diluted with dichloromethane 
(20 mL) and filtered through a pad of celite. The pad was rinsed until the filtrate was col-
ourless. The solvent was then evaporated under reduced pressure and the residue was purified 
by flash chromatography (SiO2). Tetrahydroprotoberberines give an orange-red colour with 
Dragendorff reagent. 
General procedure for the synthesis of 8-oxoprotoberberines. A mixture of cycloadduct 
(0.1 mmol) and MnO2 (10 mmol) in dry dichloromethane (20 mL) was stirred and refluxed 
under nitrogen atmosphere for 24 h. The reaction mixture was cooled to room temperature, 
diluted with dichloromethane (20 mL) and filtered through a pad of celite. The colour of 
filtrate was fluorescent yellow. The celite pad was rinsed with ethyl acetate until the filtrate 
was colourless. The solvent was then evaporated under reduced pressure and the residue was 
purified by flash chromatography (SiO2). 8-Oxoprotoberberines give specific colours with 
Dragendorff reagent. 
Biology 
Cell culture. Human cervix adenocarcinoma (HeLa) and human melanoma (Fem-x) cells 
were cultured as monolayers. Human chronic myelogenous leukaemia (K562) cells were 
grown in a suspension in nutrient medium. The cancer cell lines were obtained from the 
American Type Culture Collection (Manassas, VA, USA). The complete nutrient medium was 
RPMI 1640 supplemented with 3 mM L-glutamine, 100 μg mL-1 streptomycin, 100 IU mL-1 
penicillin, 10 % heat-inactivated (56 °C) foetal bovine serum and 25 mM Hepes adjusted to 
pH 7.2 with a bicarbonate solution. The cells were grown at 37 °C in an atmosphere of 5 % 
CO2 and humidified air. RPMI 1640, L-glutamine and Hepes were obtained from PAA 
(Pasching, Austria). 
Cell sensitivity analysis. The HeLa and Fem-x cells were seeded (2000 cells per well) 
into 96-well microtiter plates, and 20 h later, after cell adherence, five different concentrations 
of the test compounds were added to different wells. The final concentrations of the test 
compounds were from 12.5 to 200 μM. Only nutrient medium was added to the cells in the 
control wells. For the K562 cells, the test compounds were added to cell suspensions (3000 
cells per well) 2 h after cell seeding, at the same final concentrations as applied to the HeLa 
and Fem-x cells. All of the experiments were performed in triplicate. Nutrient medium with 
the corresponding concentrations of the test compounds, but void of cells, was used as the 
blank. Cisplatin was used as a positive control. 
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Determination of target-cell survival. Cell survival was determined by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test according to the method of 
Mosmann65 and modified by Ohno and Abe.66 Briefly, 20 μL MTT solution (5 mg mL-1 in 
phosphate buffered saline) was added to each well. The samples were incubated for a further 4 
h at 37 °C in 5 % CO2 with a humidified atmosphere. Then, 100 mL 10 % sodium dodecyl 
sulphate (SDS) was added to each of the wells, and the absorbance of the cell medium from 
each well was measured at 570 nm the next day. To calculate the cell survivals (%), the 
absorbance at 570 nm of each of the samples with cells grown in the presence of the test 
compounds were divided by the absorbance of the control sample (the absorbance of cells 
grown in nutrient medium only), after the subtraction of the blank sample absorbance. The 
IC50 was defined as the concentration of the agent that inhibited cell survival by 50 %, 
compared to the vehicle-treated control. 
Cell cycle analysis. The cellular DNA content and cell distribution were quantified by 
flow cytometry using propidium iodide (PI). HeLa cells were incubated in the presence of two 
different concentrations (corresponding to the IC50 and IC90 values determined after 72 h) of 
the examined compounds for 24 h. After these incubation times, the target cells were 
collected, washed and fixed in 70 % ethanol on ice. The samples were stored at –20 °C for one 
week before staining. The HeLa cells were washed in PBS, resuspended in 500 μL of staining 
solution (PBS containing RNAse A at a final concentration of 200 μg mL-1, and propidium 
iodide (PI) at a final concentration of 20 μg mL-1), and incubated for 30 min at 37 °C. The cell 
cycle phase distribution was determined using a FACSCalibur Flow Cytometer (BD Bio-
sciences, Franklin Lakes, NJ, USA). The data (10,000 events collected for each sample) were 
analyzed using CELLQuest software (BD Biosciences).67 
Morphological evaluation of HeLa cell death. Morphological features of HeLa cell death 
induced by investigated compounds were analyzed after staining the treated cells with a 
mixture of acridine orange (AO) and ethidium bromide (EB).68 Briefly, 1×105 HeLa cells 
were seeded on a glass slide in Petri dishes, and treated the next day with 2×IC50 concen-
tration of the investigated compounds for 24 h. Then, the cells were stained with 15 μL of a 
mixture of the working concentration of AO/EB (3 μg mL-1 AO and 10 μg mL-1 EB in phos-
phate buffered saline (PBS) and visualized under a fluorescence microscope using a fluores-
cein isothiocyanate (FITC) filter set. 
Computational chemistry 
Ligand preparation. Structures of the 12 biologically evaluated protoberberines were 
modelled in MarvinSketch 5.10.169 and saved in MDL .mol format. To determine the pro-
tonation state of the studied compounds for docking studies, the pKa values were predicted 
using the corresponding MarvinSketch plugin. All of the modelled structures were further 
processed in Vega ZZ 3.0.70,71 SP4 atom types and Gasteiger charges were assigned before 
running an AMMP systematic conformational search involving all flexible torsions, with 10 
steps per torsion and a 100 step conjugate gradients minimization of each generated 
conformation. The lowest energy conformer for each structure was saved in .mol2 format and 
prepared for docking studies using AutoDock Tools 1.5.6,72 whereby .pdbqt ligand files were 
generated. All flexible torsions were retained as active. 
Target pool construction and receptor files preparation. A set of 126 antitumour-related 
targets previously compiled and used in inverse docking studies73 served as the basis for the 
target pool used in this study. Online server idTarget74 was used to preliminary identify a 
subset of the 126 targets with which the most potent of the studied protoberberines (18b) 
could favourably interact. As the aim of the virtual screening was to rationalize the mech-
_________________________________________________________________________________________________________________________
(CC) 2016 SCS. All rights reserved.
Available on line at www.shd.org.rs/JSCS/
 STUDY OF NOVEL SYNTHETIC PROTOBERBERINES 119 
anism of the observed antiproliferative activity, targets the inhibition of which could not 
account for the cell cycle arrest and induction of apoptosis observed in the studied cell lines 
(e.g., matrix metalloproteinases, some cathepsins) were excluded to refine the target pool. 
Additionally, a literature search was conducted to identify targets that had previously been 
implicated in the mode of action of naturally occurring and synthetically derived proto-
berberines and related structures. These targets were used to expand the initial subset if their 
crystallographic structures were available. In total, 58 targets were screened with multiple pdb 
entries for some proteins. 
The structures of all the macromolecules in the final target pool were downloaded from 
the Protein Data Bank and processed in AutoDock Tools by removing water molecules and 
co-crystallized ligands, adding polar hydrogens and assigning Gasteiger charges. The recep-
tors were treated as rigid. The centres of the grid box for the docking studies were defined 
with respect to the spatial centre of the co-crystallized ligand. For most receptors, the grid box 
dimensions were 18 Å×18 Å×18 Å which allowed for free rotation of all the studied proto-
berberine structures and completely covered the binding site of the co-crystallized ligand. If 
the binding site extended beyond these dimensions, the grid box was enlarged correspond-
ingly. 
Virtual screening. Docking of the 12 biologically evaluated protoberberines against the 
final pool of targets was performed using AutoDock Vina75 and AUDocker LE as a graphical 
user interface facilitating virtual screening applications of AutoDock Vina.76 The level of 
exhaustiveness was set at 16 while the remaining Vina docking parameters were retained at 
their default values. Ten independent runs were performed for both protonated and neutral 
forms of all the ligands and the mean values of the docking scores corresponding to the lowest 
energy binding mode were saved for further analysis. For ligands whose pKa values would 
allow both ionized and neutral species to exist at the physiological pH of 7.4, the docking 
scores corresponding to the energetically more favourable interaction with each target were 
chosen. 
As it was previously demonstrated that unprocessed docking scores against a set of 
various protein structures do not reveal the most likely putative targets, the prioritization of 
virtual screening hits was based on how well the obtained arrays of binding energies corres-
pond to in vitro activity. To determine this, mean docking scores and IC50 values for all com-
pounds that were considered active in the MTT test (IC50 ≤ 150 μM) were imported into 
RapidMiner 577 and a correlation matrix was calculated. Pairwise correlation coefficients for 
each cell line and putative targets were ranked in descending order and analyzed. To further 
refine the results, the 10 targets with the highest correlation coefficients were chosen and their 
co-crystallised ligands were docked using previously described procedures to obtain the 
AutoDock Vina docking scores. These results were then used to compute normalized docking 
results based on ligand efficiencies,78,79 as presented in Eq. (1) and as previously described:73  






δ = =  (1) 
where δLE represents the normalized docking score, LE the ligand efficiency for the screened 
ligand (LIG) versus the LE of the co-crystallised (REF) ligand, calculated by dividing the 
corresponding docking scores (ΔG) by the number of non-hydrogen atoms (N) in the res-
pective compound. Targets with the higher sum of δLE for the active compounds were prior-
itized over those with lower sums of the normalized docking scores. 
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CONCLUSIONS 
A series of novel protoberberine-like compounds were synthesised and their 
anticancer potential was displayed on K562, HeLa and FemX cell lines. Further 
computational exploration provided insight into the potential mechanism of their 
action, suggesting that they probably act through multiple pathways. Several put-
ative biological targets for these molecules were recognized while a docking 
study indicated possible directions for their further derivatisation, favouring 
modifications of the terminal ring D. The outlined synthesis provides control 
over the substitution pattern of the ring D and this potential combined with func-
tionalised heterocycles, as starting materials, bearing substituted ring A, may 
provide access to a wider range of protoberberine-inspired compounds. Based on 
the presented results, it is believed that the flexibility of the synthetic route asso-
ciated with results of the computational study may lead to rationally designed 
compounds with significantly improved potency and selectivity profiles, work 
that is presently ongoing.  
SUPPLEMENTARY MATERIAL 
Spectral data for synthesised compounds and copies of selected NMR spectra are avail-
able electronically from http://www.shd.org.rs/JSCS/, or from the corresponding author on 
request.  
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И З В О Д  
СИНТЕЗА, ЦИТОТОКСИЧНОСТ И РАЧУНАРСКА СТУДИЈА НОВИХ 
ПРОТОБЕРБЕРИНСКИХ ДЕРИВАТА  
МИЛЕНА Р. СИМИЋ1, АНА Б. ДАМЈАНОВИЋ2, МАРКО Д. КАЛИНИЋ3, ГОРДАНА Д. ТАСИЋ1, 
СЛАВИЦА М. ЕРИЋ3, ЈЕЛЕНА А. АНТИЋ-СТАНКОВИЋ4 и ВЛАДИМИР М. САВИЋ1 
1Универзитет у Београду, Фармацеутски факултет, Катедра за органску хемију, Војводе Степе 450, 
11221 Београд, 2Институт за онкологију и радиологију, Одељење за експерименталну онкологију, 
Пастерова 14, 11000 Београд, 3Универзитет у Београду, Фармацеутски факултет, Катедра за 
фармацеутску хемију, Војводе Степе 450, 11221 Београд и 4Универзитет у Београду, Фармацеутски 
факултет, Катедра за имунологију и микробиологију, Војводе Степе 450, 11221 Београд 
Развијен је нов и ефикасан синтетски пут за добијање протоберберинских деривата. 
Ова методологија, базирана пре свега на супституцији крајњег прстена, примењена је за 
добијање мале серије ових jедињења. Њихово почетно биолошко профилисање указало 
је на антипролиферативни потенцијал. Рачунарским методама идентификована су 
потенцијална циљна места дејства и установљена рационална основа за даље структурне 
модификације. Иако активност синтетисаних деривата захтева додатно унапређење, ова 
студија је показала да описани приступ може бити користан у креирању нових водећих 
молекула.  
(Примљено 25. маја, ревидирано 19. октобра, прихваћено 26. октобра 2015) 
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